-
公开(公告)号：US20180303840A1
公开(公告)日：2018-10-25
申请号：US15768462
申请日：2016-10-14
发明人： Vivek Saroj Kumar Chopra , Jorge DiMartino , Laurie A. Kenvin , Robert Douglas Knight , Kyle MacBeth , Krishnan Viswanadhan , Qiang Xu , Samuel V. Agresta
摘要： Provided are methods and compositions for treating cancers in patients carrying an IDH2 mutation using a combination of an inhibitor of a mutant IDH2 enzyme and a DNA demethylating agent.
-
公开(公告)号：US10695352B2
公开(公告)日：2020-06-30
申请号：US15768462
申请日：2016-10-14
发明人： Vivek Saroj Kumar Chopra , Jorge DiMartino , Laurie A. Kenvin , Robert Douglas Knight , Kyle MacBeth , Krishnan Viswanadhan , Qiang Xu , Samuel V. Agresta
IPC分类号： A61K31/53 , A61K31/7068 , A61P35/02 , A61K31/706
摘要： Provided are methods and compositions for treating cancers in patients carrying an IDH2 mutation using a combination of an inhibitor of a mutant IDH2 enzyme and a DNA demethylating agent.
-
公开(公告)号：US11241423B2
公开(公告)日：2022-02-08
申请号：US16436819
申请日：2019-06-10
申请人： Celgene Corporation
发明人： Brian E. Cathers , Joshua Hansen , Ehab M. Khalil , Antonia Lopez-Girona , Kyle MacBeth , Hon-Wah Man , George W. Muller , Michael Pourdehnad , Raj Raheja
IPC分类号： A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D401/04 , C07D401/14 , C07D209/34
摘要： Compounds of formula I for treating, preventing or managing cancer are disclosed. Also disclosed are methods of treating, preventing or managing cancer, such as leukemia, comprising administering the compounds. In certain embodiments, the method of treatment comprise administering a compound provided herein in combination with a second agent. Pharmaceutical compositions and single unit dosage forms comprising the compounds are also disclosed.
-
公开(公告)号：US20170007590A1
公开(公告)日：2017-01-12
申请号：US15275045
申请日：2016-09-23
申请人： Celgene Corporation
发明人： Brian E. Cathers , Matthew Daniel Correa , Joshua Hansen , Antonia Lopez-Girona , Ehab M. Khalil , Kyle MacBeth , Hon-Wah Man , George W. Muller , Michael Pourdehnad , Raj Raheja
IPC分类号： A61K31/454 , A61K31/4545 , A61K31/501 , A61K31/496 , A61K31/506 , A61K45/06 , A61K31/5377
CPC分类号： A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D209/34 , C07D401/04 , C07D401/14
摘要： Compounds of formula I for treating, preventing or managing cancer are disclosed. Also disclosed are methods of treating, preventing or managing cancer, such as leukemia, comprising administering the compounds. In certain embodiments, the method of treatment comprise administering a compound provided herein in combination with a second agent. Pharmaceutical compositions and single unit dosage forms comprising the compounds are also disclosed.
摘要翻译： 公开了用于治疗，预防或控制癌症的式I化合物。 还公开了治疗，预防或治疗诸如白血病的癌症的方法，包括施用化合物。 在某些实施方案中，治疗方法包括给予本文提供的与第二药剂组合的化合物。 还公开了包含该化合物的药物组合物和单一单位剂型。
-
公开(公告)号：US20200163948A1
公开(公告)日：2020-05-28
申请号：US16436819
申请日：2019-06-10
申请人： Celgene Corporation
发明人： Brian E. Cathers , Matthew Daniel Correa , Joshua Hansen , Ehab M. Khalil , Antonia Lopez-Girona , Kyle MacBeth , Hon-Wah Man , George W. Muller , Michael Pourdehnad , Raj Raheja
IPC分类号： A61K31/454 , C07D401/14 , C07D401/04 , A61K45/06 , A61K31/5377 , A61K31/506 , A61K31/501 , A61K31/496 , A61K31/4545
摘要： Compounds of formula I for treating, preventing or managing cancer are disclosed. Also disclosed are methods of treating, preventing or managing cancer, such as leukemia, comprising administering the compounds. In certain embodiments, the method of treatment comprise administering a compound provided herein in combination with a second agent. Pharmaceutical compositions and single unit dosage forms comprising the compounds are also disclosed.
-
公开(公告)号：US09968596B2
公开(公告)日：2018-05-15
申请号：US15723065
申请日：2017-10-02
申请人： Celgene Corporation
发明人： Brian E. Cathers , Matthew Daniel Correa , Joshua Hansen , Antonia Lopez-Girona , Ehab M. Khalil , Kyle MacBeth , Hon-Wah Man , George W. Muller , Michael Pourdehnad , Raj Raheja
IPC分类号： A61K31/454 , C07D209/34 , A61K45/06 , C07D401/14 , C07D401/04 , A61K31/4545 , A61K31/5377 , A61K31/501 , A61K31/506 , A61K31/496
CPC分类号： A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D209/34 , C07D401/04 , C07D401/14
摘要： Compounds of formula I for treating, preventing or managing cancer are disclosed. Also disclosed are methods of treating, preventing or managing cancer, such as leukemia, comprising administering the compounds. In certain embodiments, the method of treatment comprise administering a compound provided herein in combination with a second agent. Pharmaceutical compositions and single unit dosage forms comprising the compounds are also disclosed.
-
7.发明申请METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS 审中-公开用于确定治疗大型B细胞淋巴瘤，多发性骨髓瘤和甲状腺癌的药物效果的方法公开(公告)号：US20160313300A1
公开(公告)日：2016-10-27
申请号：US15101869
申请日：2014-12-05
申请人： CELGENE CORPORATION
发明人： Matthew William Burnell Trotter , Patrick Hagner , Courtney G. Havens , Rajesh Chopra , Anita Gandhi , Anke Klippel , Maria Yinglin Wang , Mike Breider , Suzana Sturlini Couto , Yan Ren , Paul Hollenbach , Kyle MacBeth
IPC分类号： G01N33/50 , C12Q1/68 , A61K31/5377 , G01N33/68 , A61K31/454 , A61K31/517 , G01N33/574 , A61K38/21
摘要： Provided herein, in some embodiments, are methods of using certain cereblon-associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound.
摘要翻译： 在一些实施方案中，提供了使用某些与诸如Aiolos，Ikaros，干扰素（IFN）和IFN途径蛋白（酪蛋白激酶1，α1（CSNK1A1）和ZFP9）相关的蛋白相关蛋白作为生物标志物的方法 在预测和监测患有各种疾病和障碍的患者（例如弥漫性大B细胞淋巴瘤（DLBCL），多发性骨髓瘤（MM），骨髓增生异常综合征（MDS）和急性髓细胞性疾病的患者中的某些化合物的临床敏感性和治疗反应 白血病（AML））和IFN相关疾病。 本文还在某些实施方案中提供了确定免疫调节化合物的功效的方法。
-
公开(公告)号：US20190030018A1
公开(公告)日：2019-01-31
申请号：US16024581
申请日：2018-06-29
申请人： Celgene Corporation
发明人： Tonia J. Buchholz , James Carmichael , Soraya Carrancio , Jinhong Fan , Rajan Gupta , Gang Lu , Kyle MacBeth , Emily Pace , Daniel Pierce , Michael Pourdehnad , Yu Pu , Peng Wang , Naijun Wu , Sheena Yao
IPC分类号： A61K31/454 , A61K47/40 , A61K9/00 , A61K45/06 , A61K31/436 , A61K9/19 , A61P35/02
摘要： Provided herein are formulations and methods of use of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.
-
公开(公告)号：US09499514B2
公开(公告)日：2016-11-22
申请号：US14795837
申请日：2015-07-09
申请人： Celgene Corporation
发明人： Joshua Hansen , Matthew Daniel Correa , Raj Raheja , Antonia Lopez-Girona , Hon-Wah Man , George W. Muller , Ehab M. Khalil , Kyle MacBeth , Brian E. Cathers , Michael Pourdehnad
IPC分类号： A61K31/454 , C07D401/14 , C07D401/04 , A61K31/4545 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D209/34
CPC分类号： A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D209/34 , C07D401/04 , C07D401/14
摘要： Compounds of formula I for treating, preventing or managing cancer are disclosed. Also disclosed are methods of treating, preventing or managing cancer, such as leukemia, comprising administering the compounds. In certain embodiments, the method of treatment comprise administering a compound provided herein in combination with a second agent. Pharmaceutical compositions and single unit dosage forms comprising the compounds are also disclosed.
摘要翻译： 公开了用于治疗，预防或控制癌症的式I化合物。 还公开了治疗，预防或治疗诸如白血病的癌症的方法，包括施用化合物。 在某些实施方案中，治疗方法包括给予本文提供的与第二药剂组合的化合物。 还公开了包含该化合物的药物组合物和单一单位剂型。
-
公开(公告)号：US11590117B2
公开(公告)日：2023-02-28
申请号：US16920267
申请日：2020-07-02
申请人： Celgene Corporation
发明人： Soraya Carrancio , Paul Hollenbach , Antonia Lopez-Girona , Kyle MacBeth , Michael Pourdehnad , Irit Rappley , Gang Lu
IPC分类号： A61K31/454 , A61K9/00 , A61K9/19
摘要： Provided herein are methods of treating, preventing, managing, and/or ameliorating leukemia or myelodysplastic syndrome comprising administering 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, an isotopologue, pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof to a patient.
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.034 秒)
